The FDAs approval was backed by data from the Phase III KEYNOTE-A18 study, where Keytruda plus CRT reduced the risk of disease progression or death by 41% versus placebo plus CRT, Merck reported
The wound healing cascade and GHK-Cu: Normal wound healing occurs in four overlapping phases: Hemostasis clotting Inflammation immune cell recruitment Proliferation new tissue formation Remodeling scar maturation GHK-Cu appears to favorably influence phases 2, 3, and 4 simultaneously: In the inflammatory phase , it reduces pro-inflammatory cytokines (IL-6, TNF-) while preserving necessary immune signaling In the proliferative phase , it stimulates keratinocyte migration and fibroblast proliferation, accelerating epithelial coverage In the remodeling phase , it promotes type I collagen deposition over type III (scar) collagen, leading to better scar outcomes This multi-phase tissue repair activity makes GHK-Cu a compound of interest when studied alongside other regenerative peptides
Bacterial cultures, or an equivalent volume of 10% (v/v) FBS-HI in Brucella broth (mock infection control), were diluted in co-culture medium (DMEM or RPMI 1640 supplemented with 10% (v/v) Brucella broth and 5% (v/v) FBS-HI) to achieve an MOI of 35 or 50
GHK-Cu is primarily studied for skin regeneration, wound healing, collagen stimulation, anti-inflammatory signaling, antioxidant defense, hair follicle health, and broad gene expression modulation
